- Price
- $228.20
- Day
- -2.21%
- Mkt Cap
- $37.56B
- 52W Range
- $154.50 – $251.36
- Volume
- 1.05M
- Beta
- 1.20
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
IQVIA Holdings Inc. (NYSE: IQV - Get Free Report) insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company's stock,
Read full article
The transaction involved the disposal of 558 shares at an exact weighted-average price of $245.21 per share on July 29, 2026. The sale reduced the insider's direct equity holdings by 16%, leaving 2,989 shares held directly.
Read full article
The transaction involved the sale of 5,000 shares at $249.16 per share, representing a total value of about $1.2 million. This disposition resulted in a 19% reduction of the insider total direct equity holdings in the company.
Read full article
The CEO of IQVIA executed an exercise-and-sell of stock appreciation rights involving shares at a weighted average price of $245.51 on July 29, 2026. Bousbib maintains substantial equity exposure through roughly 836,000 directly held shares and about 543,000 shares held indirectly via the Orohena Trust.
Read full article
Amundi lowered its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 19.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 869,003 shares of the medical research company's stock after selling 206,218 shares during the period. Amundi owned 0.52% of IQVIA worth $148,200,000 as
Read full article
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
Read full article
IQVIA Holdings Inc. operates behind the scenes, running clinical trials and processing vast healthcare data for pharmaceutical companies. IQV's business spans clinical trial management, healthcare data analytics, software products, and consulting, providing diversified revenue streams. I previously rated IQV a Buy due to strong results and robust demand, but concerns over slowing guidance, CSMS segment weakness, and regulatory risks tempered my enthusiasm.
Read full article
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.
Read full article
IQVIA Holdings (IQV) came out with quarterly earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.02 per share. This compares to earnings of $2.81 per share a year ago.
Read full article
IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong demand for its healthcare data and analytics services, sending its shares up 11% before the bell.
Read full article
IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share.
Read full article